These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 23886909)

  • 1. The role of complement in mAb-based therapies of cancer.
    Taylor RP; Lindorfer MA
    Methods; 2014 Jan; 65(1):18-27. PubMed ID: 23886909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytotoxic mechanisms of immunotherapy: Harnessing complement in the action of anti-tumor monoclonal antibodies.
    Taylor RP; Lindorfer MA
    Semin Immunol; 2016 Jun; 28(3):309-16. PubMed ID: 27009480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients.
    Beurskens FJ; Lindorfer MA; Farooqui M; Beum PV; Engelberts P; Mackus WJ; Parren PW; Wiestner A; Taylor RP
    J Immunol; 2012 Apr; 188(7):3532-41. PubMed ID: 22368276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complement in monoclonal antibody therapy of cancer.
    Rogers LM; Veeramani S; Weiner GJ
    Immunol Res; 2014 Aug; 59(1-3):203-10. PubMed ID: 24906530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complement function in mAb-mediated cancer immunotherapy.
    Gelderman KA; Tomlinson S; Ross GD; Gorter A
    Trends Immunol; 2004 Mar; 25(3):158-64. PubMed ID: 15036044
    [No Abstract]   [Full Text] [Related]  

  • 6. Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer.
    Meyer S; Leusen JH; Boross P
    MAbs; 2014; 6(5):1133-44. PubMed ID: 25517299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complement in antibody-based tumor therapy.
    Derer S; Beurskens FJ; Rosner T; Peipp M; Valerius T
    Crit Rev Immunol; 2014; 34(3):199-214. PubMed ID: 24941073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New perspectives on complement mediated immunotherapy.
    Stasiłojć G; Österborg A; Blom AM; Okrój M
    Cancer Treat Rev; 2016 Apr; 45():68-75. PubMed ID: 26994325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myeloid cells as effector cells for monoclonal antibody therapy of cancer.
    Braster R; O'Toole T; van Egmond M
    Methods; 2014 Jan; 65(1):28-37. PubMed ID: 23811299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A bispecific monoclonal antibody directed against both the membrane-bound complement regulator CD55 and the renal tumor-associated antigen G250 enhances C3 deposition and tumor cell lysis by complement.
    Blok VT; Daha MR; Tijsma O; Harris CL; Morgan BP; Fleuren GJ; Gorter A
    J Immunol; 1998 Apr; 160(7):3437-43. PubMed ID: 9531304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beta-glucan enhanced killing of renal cell carcinoma micrometastases by monoclonal antibody G250 directed complement activation.
    Sier CF; Gelderman KA; Prins FA; Gorter A
    Int J Cancer; 2004 May; 109(6):900-8. PubMed ID: 15027124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complement System: a Neglected Pathway in Immunotherapy.
    Bordron A; Bagacean C; Tempescul A; Berthou C; Bettacchioli E; Hillion S; Renaudineau Y
    Clin Rev Allergy Immunol; 2020 Apr; 58(2):155-171. PubMed ID: 31144209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mapping of binding epitopes of a human decay-accelerating factor monoclonal antibody capable of enhancing rituximab-mediated complement-dependent cytotoxicity.
    Guo B; Ma ZW; Li H; Xu GL; Zheng P; Zhu B; Wu YZ; Zou Q
    Clin Immunol; 2008 Aug; 128(2):155-63. PubMed ID: 18502181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lysis of human tumor cell lines by canine complement plus monoclonal antiganglioside antibodies or natural canine xenoantibodies.
    Helfand SC; Hank JA; Gan J; Sondel PM
    Cell Immunol; 1996 Jan; 167(1):99-107. PubMed ID: 8548851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complement as a Biological Tool to Control Tumor Growth.
    Macor P; Capolla S; Tedesco F
    Front Immunol; 2018; 9():2203. PubMed ID: 30319647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of complement by monoclonal antibodies that target cell-associated β₂-microglobulin: implications for cancer immunotherapy.
    Pokrass MJ; Liu MF; Lindorfer MA; Taylor RP
    Mol Immunol; 2013 Dec; 56(4):549-60. PubMed ID: 23911412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The complement system in cancer: Ambivalence between tumour destruction and promotion.
    Mamidi S; Höne S; Kirschfink M
    Immunobiology; 2017 Jan; 222(1):45-54. PubMed ID: 26686908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complement and cellular cytotoxicity in antibody therapy of cancer.
    Wang SY; Weiner G
    Expert Opin Biol Ther; 2008 Jun; 8(6):759-68. PubMed ID: 18476787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumour effects of single or combined monoclonal antibodies directed against membrane antigens expressed by human B cells leukaemia.
    Loisel S; André PA; Golay J; Buchegger F; Kadouche J; Cérutti M; Bologna L; Kosinski M; Viertl D; Delaloye AB; Berthou C; Mach JP; Boumsell L
    Mol Cancer; 2011 Apr; 10():42. PubMed ID: 21504579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions.
    Battella S; Cox MC; Santoni A; Palmieri G
    J Leukoc Biol; 2016 Jan; 99(1):87-96. PubMed ID: 26136506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.